biotech news today glp-1 The arms race just got a new contender. Structure Therapeutics' oral pill aleniglipron cleared a mid-stage trial with clinically meaningful weight loss and a clean safety profile. Phase 3 is now FDA approves first GLP-1 pill

Adenosine, produced in response to tumor hypoxia, is another key driver of angiogenesis, promoting HIF-1 stabilization and VEGF production through ligation of the A2AR (203, 204)

GLP-1 medications work by mimicking the GLP-1 hormone our bodies naturally produce when we eat

More efficient drugs : the first versions of the drug help people achieve a 5 to 15% bodyweight loss, new versions currently in trials are showing results of about 25

Orforglipron In phase II, randomized, double-blind study, adults with overweight or obesity and without T2DM who took oral orforglipron (12, 24, 36, or 45 mg) daily for 36 weeks experienced a weight reduction of 9.414.7% [105]

& Pan, D

This leads us to the next critical subject